????????????
Dawnrays Pharmaceutical (Holdings) Limited(Incorporated in the Cayman Islands with limited liability ??????????????)
Suites 3212-13, Tower Two, Times Square, 1 Matheson Street, Hong Kong
Tel: 852-2111 9708 Fax: 852-2111 9870
FOR IMMEDIATE RELEASE PRESS RELEASE Attn: Business Editor
Dawnrays Pharmaceutical (Holdings) Limited
Announced Annual Results For The Year Ended 31 December
2011
Net profit after tax dropped 12.3% to RMB 146.31 million
A final dividend of HK$ 0.068 per share was declared
(Hong Kong, 23 March 2011) Dawnrays Pharmaceutical (Holdings)
Limited
("Dawnrays Pharma" or the "Group", The Stock Exchange of Hong
Kong Stock Code:
2348) announced annual results for the year ended 31 December
2011. Turnover amounted to approximately RMB 1,081,044,000
(2009: RMB 1,286,683,000), representing an decrease of 16%
compared with the corresponding period of last year. Profit
attributable to owners of the parent amounted to
approximately RMB 146,307,000 (2009: RMB 166,840,000),
representing an decrease of 12.3% when compared to that of
last year. Basic earnings per share was approximately RMB
0.1834 (2009: RMB 0.2104). The Board recommends the payment
of a final dividend of HK$ 0.068 per share for the year ended
31 December 2011 (2010: HK$ 0.078). Taking into consideration
the interim dividend of HK$ 0.02 per share, the total annual
dividend distributed for the year is HK$ 0.088 per share
(2010: HK$ 0.098). The dividend payout ratio is approximately
39.1%.
Ms. Li Kei Ling, Chairman of Dawnrays Pharma, said, "2011
marks the third year into the in-depth medical reforms pushed
forward by the Central Government and is also under the "12th
Five-Year Development Plan". During the year, the government
introduced a number of substantial policies, plans, guidance
and measures in connection with the pharmaceutical industry.
As regards the policies which might have immediate effect on
the pharmaceutical industry, in addition to the 2 notices
issued by the National Development and Reform Commission
concerning adjustment to the retail price of pharmaceuticals,
the stringent requirements stipulated in both the
"Good Manufacturing Practice of Pharmaceuticals (revised in
2010)(????????
??? (2010 ??? ) ? )" ("New GMP") promulgated by the State Food and Drug
1
Administration and the "Administrative Measures regarding
Clinical Application of Antibacterial Medicines (Consultation
Paper)(?????????????(???? ?)?)" issued by the
Ministry of Health also have a bearing on the
pharmaceutical
industry to some extent.
"
Looking back at 2011, With the Company's success in
implementing various plans under its development strategies,
the Group recorded impressive return on its investments in
system specific medicines for cardiovascular diseases, etc.
Market share has become bigger and sales continued to post
considerable growth while gross margins maintained at a
satisfactory level. The increasingly strong product structure
of the Group's system specific medicines warrants the
profitability of the Company and has partially offset the
effect of the declining revenue from cephalosporin products.
Besides, the Group adheres to its business policy of healthy
development and its financial principle of strict cost
control. Cash flows from operating activities for 2011 were
RMB82,986,000 (2010: RMB252,344,000).
In 2011, the Group has obtained from the State Food and Drug
Administration (SFDA)
1 new drug certificate for Potassium Citrate Extended-release
Tablets; and 4 production approvals, 2 for cephalosporin
antibiotics (Cefprozil Tablets and Cefodizime Sodium for
Injection) and 2 for specific medicines (Levamlodipine
Besylate Tablets and Potassium Citrate Extended-release
Tablets). We have completed clinical studies for 3 types of
medicine, 2 for specific medicines treating
cardio-cerebrovascular diseases and 1 for oral cephalosporin
antibiotic. Proposals for
2 new products were approved and 1 patent was granted.
On-site inspection by the Certification Centre for Drugs
under SFDA in respect of the registration and production of
Prulifloxacin and its tablet form was completed.
Since 2010, the huge population base in China, rising
national income, aging population, urbanization, improvement
in social security system and so on have become the driving
force behind the rapid development of the pharmaceutical
industry. The pharmaceutical industry of China is moving
towards another decade of significant developments. We may
witness the introduction by the Chinese authorities of
various policies to optimize the medical resources. By
committing more resources and perfecting the system, the
coverage and popularity of medical service will be enhanced
and a rapid growth will also be seen in China's
pharmaceutical market. With the Company's strategic objective
in mind, the management of Dawnrays will ride on the general
trend of the nation's industrial development. Optimization of
resource allocation will be materialized by leveraging on the
strengths of the capital markets. Management standard and
operating efficiency will also be raised so as to strengthen
risk management and keep the Company on the right track of
healthy development. In achieving these goals, we are
committed to: 1) putting more efforts to R&D, optimizing
resource allocation, and expediting the launching process of
products under development to enrich our array of specific
medicines encompassing various areas; 2)obtaining GMP
certification for newly-built workshops as planned,
implementing the construction of new facilities and
manufacturing bases as well as application for international
recognition in an orderly fashion so as to raise the
2
standard of product quality and competitiveness in the market; 3) adjusting and optimizing product mix according to government policies and market demand as well as developing markets for new products and structuring the sales team as planned; and 4)further lowering cost while enhancing product quality of our existing cephalosporin products and even exploring opportunities to cooperate with enterprises at home and abroad to ensure the product line maintains profit contribution.
About Dawnrays Pharmaceutical (Holdings) Limited Dawnrays Pharmaceutical (Holdings) Limited (Stock Code: 2348) is a leading vertically integrated pharmaceutical group in China with core competencies in the manufacturing of cephalosporins and system specific medicines. Founded in 1995, the Group was listed on the Main Board of the Stock Exchange of Hong Kong in July 2003.
Dawnrays Pharma is among one of the earliest pharmaceutical
companies in China granted the GMP certification. The Group
is principally engaged in the development, manufacturing and
sales of cephalosporins and various system specific
medicines. Dawnrays Pharma is one of the few comprehensive
vertically integrated
3rd generation cephalosporin manufacturers in
China, adopting distinctive production
process from pharmaceutical intermediates to bulk medicines
and pharmaceutical preparations. Its system specific
medicines cover a wide range of therapeutic areas for
cardiovascular system, anti-viral, anti-allergic, digestive
system, urinary system and endocrine system, etc. The dosage
forms of the Group's pharmaceutical preparations include
powder for injections, tablets, capsules and granules,
etc.
- End -
3
This press release is issued by Dawnrays Pharmaceutical
(Holdings) Limited. For further enquiries, please
contact:
Vanessa Yeung / Michelle Li Corporate Communications Tel :
852-2111 9708
Fax : 852-2111 9870
Email : ir@dawnrays.com.hk
4
Dawnrays Pharmaceutical (Holdings) Limited
Announced Annual Results For The Year Ended 31 December
2011
For the year ended 31 December
2010 (Audited) RMB '000
Revenue 1,081,044 1,286,683Cost of sales (718,292) (910,526)
Gross profit 362,752 376,157
Other income and gains 16,601 9,145
Selling and distribution costs (100,861) (95,673)
Administrative expenses (55,777) (48,884) Other expenses
(41,369) (31,317) Finance costs (2,159) (549)
Profit before tax | 179,187 | 208,879 |
Income tax expense | (32,880) | (42,041) |
Profit for the year | 146,307 | 166,838 |
Attributable to : | ||
Owners of the parent | 146,307 | 166,840 |
Non-controlling interest | - | (2) |
146,307 166,838
Dividends : | ||
Interim | 13,070 | 13,726 |
Proposed final | 44,127 | 52,472 |
Earnings per share attributable to ordinary | |||
equity holders of the parent - basic, for profit for the year | RMB0.1834 | RMB0.2104 | |
- diluted, for profit for the year | RMB0.1826 | RMB0.2093 |
5
distributed by | This press release was issued by Dawnrays Pharmaceutical (Holdings) Ltd. and was initially posted at http://202.66.146.82/listco/hk/dawnrays/annual/2011/respress.pdf . It was distributed, unedited and unaltered, by noodls on 2012-03-24 04:20:25 AM. The issuer is solely responsible for the accuracy of the information contained therein. |